Skip to main content
logo
L&K Biomed Ltd. (KOSDAQ:156100)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,450.00
-140.00 (-2.50%)
At close: Sep 11, 2026

L&K Biomed Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
39,94238,92036,09229,90519,76715,373
Revenue Growth
-0.11%7.84%20.69%51.28%28.59%-20.58%
Gross Profit
33,18332,02230,14225,67814,7927,354
Operating Income
338.96715.123,0782,034-12,738-15,280
Net Income
2,766-16,2979,743-1,867-13,625-9,669
Earnings Per Share
128.57-801.67448.00-115.17-1017.14-722.29
EPS Growth
39.27%-----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
21,2496,28619,94312,77613,00319,216
Total Debt
29,21619,14823,39713,51325,20122,456
Net Cash (Debt)
-7,967-12,861-3,454-737.76-12,198-3,240
Net Cash Growth
------
Net Cash Per Share
-370.33-632.68-158.80-45.50-910.57-242.05

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-4,598-13,879-7,430-1,370-6,881-10,600
Capital Expenditures
-4,919-2,991-584.84-2,047196.7498.75
Free Cash Flow
-9,517-16,870-8,015-3,417-6,684-10,501
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
83.08%82.28%83.52%85.87%74.83%47.84%
Operating Margin
0.85%1.84%8.53%6.80%-64.44%-99.40%
Pretax Margin
4.54%-44.05%27.19%-21.63%-82.45%-57.88%
Profit Margin
6.93%-41.87%27.00%-6.24%-68.93%-62.90%
FCF Margin
-23.83%-43.34%-22.21%-11.43%-33.81%-68.31%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
42.39-13.57---
Forward PE
-19.6719.6726.7225.0225.02
PS Ratio
3.057.003.666.795.439.37